Avandia Side Effects
The most common Avandia (rosiglitazone) side effects are upper respiratory tract infection, headache, back pain, high blood sugar, fatigue, sinusitis, diarrhea and low blood sugar. Serious side effects of Avandia include: heart failure, heart attack, liver damage and bone fracture.
A 2007 article by cardiologist Steven Nissen and Kathy Wolski of the Cleveland Clinic first exposed Avandia’s association with serious heart-related side effects. Other studies have linked the drug to liver failure and an increased risk of pregnancy.
- Discomfort in the chest that feels like pressure, squeezing, fullness, or pain
- Pain or discomfort in the arms, back, neck, jaw, or stomach
- Shortness of breath
- Swelling or weight gain
- Changes in menstrual cycles
- Bone fracture
- Abdominal pain
- Dark urine
- Yellowing of the eyes or skin
- Persistent nausea or vomiting
- Vision problem
Approved in 1999, Avandia is used along with diet and exercise and sometimes other medicines to treat Type 2 diabetes. Through the years, it has gone from being a top-selling medication to a disgraced diabetes drug because of its risks.
Manufacturer GlaxoSmithKline set aside billions of dollars to litigate and settle thousands of Avandia lawsuits that accused the company of hiding the risks of heart attack and cardiac death from the public.
The Food and Drug Administration and GlaxoSmithKline have long recognized that rosiglitazone, the active ingredient in Avandia, may be associated with certain heart problems.
The prescribing information for all rosiglitazone-containing products has addressed the risk since 2001, but the FDA has significantly strengthened the warnings over the years.
In 2007, the FDA required GlaxoSmithKline to add a black box warning to the drug’s label to notify consumers that the drug can cause or worsen congestive heart failure in some patients. The warning also advises against use of the drug in patients with symptomatic heart failure and in patients with established New York Heart Association (NYHA) Class III or IV heart failure.
Heart Risk Deserves ‘Serious Attention’
The FDA released a safety alert about the heart risks in 2007 and sought advice from 24 experts in heart disease, epidemiology, biostatistics and endocrinology — experts that study glands and hormones and are involved in the care of patients with diabetes. On July 30, 2007, the experts convened at a joint meeting of the FDA Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee.
“After lengthy discussions, we concluded that the use of rosiglitazone for the treatment of Type 2 diabetes was associated with a greater risk of myocardial ischemic events [heart attacks] than placebo, metformin, or sulfonylureas,” Dr. Clifford J. Rosen, the joint committee chair, wrote in The New England Journal of Medicine.
The experts based their conclusion on three studies, including one that used GlaxoSmithKline’s own data. The findings of that study revealed increases in heart risks as high as 43 percent in people taking the drug.
“The basic plot of the rosiglitazone story quickly became obvious to the advisory committee: a new ‘wonder drug,’ approved prematurely and for the wrong reasons by a weakened and underfunded government agency subjected to pressure from industry, had caused undue harm to patients,” Rosen said. “The rosiglitazone story thus carries lessons for scientists, practitioners, and regulators alike.”
According to the FDA, the following organizations agreed the risk deserved “serious attention and follow-up”:
- American Association of Clinical Endocrinologists
- American College of Cardiology
- American Diabetes Association
- American Heart Association
- Endocrine Society
Heart Health Concerns Lead to FDA Restrictions
The FDA as well as outside experts have continued to study the side effects of Avandia on heart health. In 2010, the FDA announced it was significantly restricting the use of the drug to patients with Type 2 diabetes who could not control their diabetes on other medications.
“These new restrictions are in response to data that suggest an elevated risk of cardiovascular events, such as heart attack and stroke, in patients treated with Avandia,” the agency said.
The FDA has since lifted the restrictions on the drug’s use, based on newer data that did not show that it was associated with an increased risk of heart attack compared to other medications used to treat Type 2 diabetes, but the heart failure and heart problem warnings, including the black box warning, remain in the prescribing information.
The black box warning says health care professionals should carefully monitor patients for signs of heart failure after they start the drug and after each dose increase. Signs of heart failure include: excessive, rapid weight gain; difficult or labored breathing; and swelling.
GlaxoSmithKline has repeatedly updated Avandia’s label to include new information about bone fracture risk. In 2007 — eight years after the drug hit the market — a new drug label featured information about increased incidence of bone fractures in women. By October 2008, the label cautioned that the bone fracture risk may also apply to men.
The labeling changes were the result of long-term trials that found an increased frequency of bone fracture in more than 200 patients who took the drug. Drugs like rosiglitazone are said to cause slower bone formation and faster bone loss. Researchers believe the drugs trigger the body to reabsorb bone, which can make bones more likely to break.
Bone Fracture Studies
Long-term trials RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes) and ADOPT (active-controlled trials in patients with diabetes) were among the studies with findings that prompted the bone fracture warnings. An increased incidence of bone fractures, particularly in women, “was noted after the first year of treatment and persisted during the course of the trial,” according to the drug’s label.
Most fractures in the women who received the drug happened in areas not usually associated with postmenopausal osteoporosis. Bone fractures were in the upper arm, hand and foot; postmenopausal osteoporosis is associated with fractures in the hip or spine.
In 2008, Swiss researchers analyzed records of British diabetic patients with fractures and found patients on Avandia or Actos — another medication that works the same way as Avandia — had double the odds of fractures in sites other than the spine compared to patients that did not use Avandia or Actos. Patients who took the drugs for about 12 to 18 months had an even higher chance of bone fracture. The highest risk was for those with two or more years of treatment with the drugs.
This research, which was published in the journal Archives of Internal Medicine, compared the records of 1,020 diabetic patients with fractures diagnosed by British doctors between 1994 and 2005 against a control group of people with diabetes who did not have fractures.
“This analysis provides further evidence of a possible association between long-term use of [the drugs] and fractures, particularly of the hip and wrist, in patients with diabetes mellitus,” the authors wrote.
Bone Risk in Men and Younger Women
A study published in 2010 in Diabetes Obesity and Metabolism found the use of rosiglitazone is associated with an increased risk of fractures in both women and men.
The study found a significant increase in fractures in people taking the drug. It also demonstrated that the risk of bone fracture is increased even in younger women.
“Our findings add support to the growing literature that TZD treatment is associated with an increased risk of fractures in both men and women, that effects of rosiglitazone and pioglitazone are similar and that fracture risk is increased even in younger women,” the study’s authors wrote.
A different study published in Acta Diabetologica in 2015 found results consistent with the findings of previous trials that showed the drug is associated with an increased risk of bone fractures in women and probably men, too.
Before Avandia gained FDA approval in 1999, the biggest concern surrounding the drug had been whether it would cause liver toxicity. Researchers had linked a similar drug, Rezulin, to scores of confirmed cases of liver failure, and it was ultimately pulled from the market.
Records show SmithKline Beecham, which later became GlaxoSmithKline, representatives informed the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee that Avandia was not expected to damage the liver. The committee ultimately endorsed the drug and unanimously recommended FDA approval.
However, within a year of entering the market, the drug was linked to two cases of liver failure. In one case, the patient had also taken Rezulin. One of the patients died, and the other recovered without needing a liver transplant.
Since then, studies have implicated the drug in liver failure. One case series published in 2009 in Pharmacoepidemiology & Drug Safety showed evidence that rosiglitazone and pioglitazone (Actos) can cause liver problems. It found 21 cases of liver failure associated with the drugs among all cases of liver failure reported to the FDA between 1997 and 2006, although the authors noted the possibility that the drug may not have been the cause of liver failure in every case.
“This is the largest case series of liver failure associated with rosiglitazone or pioglitazone reported to date, strengthening the evidence that these drugs can cause severe hepatotoxicity [liver damage],” the authors wrote.
Today, the drug’s label warns doctors to measure their patients’ liver enzymes before starting therapy and periodically throughout treatment. Patients with abnormally high liver enzyme levels should not start taking the drug.
The drug’s label also states that Avandia should not be initiated in patients that display clinical evidence of active liver disease or in those that have increased liver enzyme levels.
Doctors should be cautious about continuing treatment in patients with mild liver enzyme elevations. These patients require “close clinical follow-up, including liver enzyme monitoring, to determine if the liver enzyme elevations resolve or worsen,” according to the drug’s label.
Other Possible Side Effects
Although heart failure, bone fractures and liver toxicity are the more well-known side effects of Avandia, the drug is also linked to other potential side effects, including swelling, weight gain, vision problems, blood and blood sugar effects, and an increased risk of pregnancy.
During controlled clinical trials, patients with Type 2 diabetes who took the drug reported mild to moderate edema, or swelling, that may have been dose related. Edema occurs when fluid becomes trapped in the body’s tissues. The drug can cause fluid retention, which can worsen or lead to congestive heart failure.
“In a clinical trial in healthy volunteers who received 8 mg of Avandia daily for 8 weeks, there was a statistically significant increase in median volume of plasma [a liquid component of blood] compared with placebo,” the drug’s label states.
Increased plasma volume can contribute to the development of edema. Edema can become increasingly painful and uncomfortable. Sometimes, the swelling causes stiffness, decreases blood circulation and makes it difficult to walk.
The side effect may be dose related, and the drug should be used with caution in people with edema. People with ongoing edema who take both insulin and Avandia have a greater chance of experiencing side effects associated with edema.
People who took Avandia by itself and in combination with other diabetes drugs during clinical trials experienced weight gain. Post-marketing reports, reports of potential additional side effects of a drug since it came to market, have also been filed for unusually rapid weight gain beyond what was seen in clinical trials. It’s unclear exactly how the drug caused users to gain weight, though it “probably involves a combination of fluid retention and fat accumulation,” according to the drug’s label.
One trial compared rosiglitazone to metformin. On average, patients who took rosiglitazone gained about 6 pounds while those who took metformin gained less than half a pound. A third of patients treated with rosiglitazone gained more than 11 pounds compared with just 7 percent of patients treated with metformin.
Patients who experience increases in their weight should be assessed for fluid accumulation as well as edema and congestive heart failure.
Some diabetic patients who were taking Avandia reported experiencing macular edema. The American Academy of Ophthalmology defines macular edema as swelling or thickening of the part of the eye known as the macula, which is responsible for detailed, central vision. Macular edema is the result of fluids leaking from blood vessels in the retina.
The macula allows a person to do things like read, sew or recognize a face. When the macula is swollen, it does not function properly. As a result, patients who developed macular edema reported blurred vision and decreased visual activity. Vision improved for some patients after they stopped taking the drug. Patients with diabetes should receive regular eye exams as part of their normal care, and should report any vision problems to their doctor.
Blood and Blood Glucose Effects
Adults treated with Avandia showed decreases in average hemoglobin, the protein found in red blood cells that carries oxygen throughout the body, and hematocrit — a blood test that determines the proportion of red blood cells in the blood. The decreases varied based on the amount of drug patients took. These blood effects could be related to the increase in plasma volume that results from taking the drug.
Patients should undergo periodic fasting blood glucose and HbA1c tests to monitor their response to the drug. People who mix antidiabetic medications may be at risk for hypoglycemia. A doctor may instruct you to reduce the dose of the other diabetes drug.
Ovulation and Pregnancy
Some premenopausal anovulatory (not ovulating) women may experience ovulation while taking this drug. This could put users at an increased risk for pregnancy while taking the drug. The label advises doctors to recommend adequate birth control methods in premenopausal women. The FDA cautions women to avoid using the drug while pregnant.
Preclinical studies showed hormonal imbalance. Women should review with their doctors the benefits of continuing treatment if unexpected menstrual changes occur.
How can we improve this page?
Thank You for Your Feedback
We appreciate your feedback. One of our content team members will be in touch with you soon.
We appreciate your feedback. One of our content team members will be in touch with you soon.
Calling this number connects you with a Drugwatch representative. We will direct you to one of our trusted legal partners for a free case review.
Drugwatch's trusted legal partners support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.